RGD-Binding Integrins in Head and Neck Cancers
AbstractAlterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy. View Full-Text
Share & Cite This Article
Ahmedah, H.T.; Patterson, L.H.; Shnyder, S.D.; Sheldrake, H.M. RGD-Binding Integrins in Head and Neck Cancers. Cancers 2017, 9, 56.
Ahmedah HT, Patterson LH, Shnyder SD, Sheldrake HM. RGD-Binding Integrins in Head and Neck Cancers. Cancers. 2017; 9(6):56.Chicago/Turabian Style
Ahmedah, Hanadi T.; Patterson, Laurence H.; Shnyder, Steven D.; Sheldrake, Helen M. 2017. "RGD-Binding Integrins in Head and Neck Cancers." Cancers 9, no. 6: 56.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.